BIO-TECHNE Corp (TECH)

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

The Compensation Committee reviews and approves each executive's compensation annually and is responsible for ensuring that compensation for the executive officers is consistent with four objectives: attracting and retaining superior executive talent to drive sustainable value creation, providing incentives that reward the achievement of performance goals that correlate to sustainable shareholder value, aligning executives' incentives with long-term shareholder interests, and ensuring market competitiveness and internal equity.

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

a. Approved under the standard stated in the filing — “| 2025 Proxy Statement 75 Back to Contents What Are the Voting Options? Voting Options Board Recommendation Vote Required to Adopt the Proposal Effect of Abstentions Effect of Broker Non-Votes* Proposal 1: Set the number of members of the Board of Directors at nine For, Against, or Abstain FOR Majority of votes present and entitled to vote Treated as a vote Against No effect Proposal 2: Elect the Company's nine nominees to the Board of Directors For, Against, or Abstain for each nominee FOR each nominee Directors who receive a greater number of "FOR" votes than "AGAINST" votes will be elected No effect No effect Proposal 3: Approve, on an advisory basis, the compensation of our executive officers For, Against, or Abstain FOR Majority of votes present and entitled to vote Treated as a vote Against No effect Proposal 4: Ratify the appointment of KPMG, LLP as the Company's independent registered public accounting firm For, Against, or Abstain FOR Majority of votes present and entitled to vote Treated as a vote Against Broker non-votes not expected * If you hold your shares in street name and do not submit voting instructions to your broker, bank, or other nominee, your broker, bank, or other nominee will not be permitted to vote your shares in their discretion on any proposals other than the proposal to ratify the independent registered public accounting firm.”.

b. Approved under the standard stated in the filing — “| 2024 Proxy Statement 76 Back to Contents What Are the Voting Options? Voting Options Board Recommendation Vote Required to Adopt the Proposal Effect of Abstentions Effect of Broker Non-Votes* Proposal 1: Set the number of members of the Board of Directors at nine For, Against, or Abstain FOR Majority of votes present and entitled to vote Treated as a vote Against No effect Proposal 2: Elect the Company's nine nominees to the Board of Directors For, Against, or Abstain for each nominee FOR each nominee Directors who receive a greater number of "FOR" votes than "AGAINST" votes will be elected No effect No effect Proposal 3: Approve, on an advisory basis, the compensation of our executive officers For, Against, or Abstain FOR Majority of votes present and entitled to vote Treated as a vote Against No effect Proposal 4: Ratify the appointment of KPMG, LLP as the Company's independent registered public accounting firm For, Against, or Abstain FOR Majority of votes present and entitled to vote Treated as a vote Against Broker non- votes not expected * If you hold your shares in street name and do not submit voting instructions to your broker, bank, or other nominee, your broker, bank, or other nominee will not be permitted to vote your shares in their discretion on any proposals other than the proposal to ratify the independent registered public accounting firm.”.

c. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

Of the companies BIO-TECHNE Corp names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including BIO-TECHNE Corp.

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.